keyword
MENU ▼
Read by QxMD icon Read
search

Liraglutide

keyword
https://www.readbyqxmd.com/read/29345505/the-pharmacological-management-of-metabolic-syndrome
#1
Julie Rask Larsen, Lorena Dima, Christoph U Correll, Peter Manu
Introduction The metabolic syndrome includes a constellation of several well-established risk factors, which need to be aggressively treated in order to prevent overt type 2 diabetes and cardiovascular disease. While recent guidelines for the treatment of individual components of the metabolic syndrome focus on cardiovascular benefits as resulted from clinical trials, specific recent recommendations on the pharmacological management of metabolic syndrome are lacking. The objective of present paper was to review the therapeutic options for metabolic syndrome and its components, the available evidence related to their cardiovascular benefits, and to evaluate the extent to which they should influence the guidelines for clinical practice...
January 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29344656/liraglutide-suppresses-proliferation-and-induces-adipogenic-differentiation-of-3t3-l1-cells-via-the-hippo-yap-signaling-pathway
#2
Yongmei Li, Jianying Du, Endong Zhu, Juanjuan Zhang, Jie Han, Wei Zhao, Bei Sun, Derun Tian
Liraglutide, as a glucagon-like peptide‑1 analogue, is used to treat type 2 diabetes mellitus and obesity. Previous findings have demonstrated the effects of liraglutide on adipogenesis; however, the underlying mechanism involved in this process remains to be elucidated. In the present study, to certify the effect of liraglutide on adipogenesis and explore the possible underlying mechanism involved in this process, preadipocyte 3T3‑L1 cells were cultured in adipocyte‑inducing medium and treated with liraglutide...
January 16, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29341461/effect-of-immediate-and-prolonged-glp-1-receptor-agonist-administration-on-uric-acid-and-its-kidney-clearance-post-hoc-analyses-of-four-clinical-trials
#3
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Petter Bjornstad, Mark H H Kramer, Michaela Diamant, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte
AIMS: To determine effects of glucagon-like peptide (GLP)-1 receptor agonists (RA) on uric acid (UA)-levels and kidney UA-clearance. MATERIAL AND METHODS: Post-hoc analyses of four controlled clinical trials, which assessed actions of GLP-1RA-administration on kidney physiology. Immediate effects of GLP-1RA exenatide-infusion versus placebo was determined in 9 healthy overweight males (Study-A) and in 52 overweight T2DM-patients (Study-B). Effects were also examined of 12-week long-acting GLP-1RA liraglutide versus placebo in 36 overweight T2DM-patients (Study-C) and of 8-week short-acting GLP-1RA lixisenatide versus once-daily titrated insulin-glulisine in 35 overweight T2DM-patients (Study-D)...
January 17, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29334278/a-comparative-safety-review-between-glp-1-receptor-agonists-and-sglt2-inhibitors-for-diabetes-treatment
#4
Agostino Consoli, Gloria Formoso, Maria Pompea Antonia Baldassarre, Fabrizio Febo
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials. Since it is therefore very likely that GLP-1RA and SGLT2i use will become more and more common, it is more and more important to gather and discuss information about their safety profile...
January 15, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29328581/liraglutide-and-renal-outcomes-in-type-2-diabetes
#5
Ian H de Boer
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328580/liraglutide-and-renal-outcomes-in-type-2-diabetes
#6
Johannes F E Mann, David D Ørsted, John B Buse
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328579/liraglutide-and-renal-outcomes-in-type-2-diabetes
#7
Simon N Thornton, Véronique Regnault, Patrick Lacolley
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328578/liraglutide-and-renal-outcomes-in-type-2-diabetes
#8
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328577/liraglutide-and-renal-outcomes-in-type-2-diabetes
#9
Giovanni Gulli
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328576/liraglutide-and-renal-outcomes-in-type-2-diabetes
#10
Lennart Tonneijck, Daniël H van Raalte, Marcel H A Muskiet
No abstract text is available yet for this article.
November 30, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29328405/liraglutide-repairs-the-infarcted-heart-the-role-of-the-sirt1-parkin-mitophagy-pathway
#11
Huiying Qiao, Haiyan Ren, He Du, Minfang Zhang, Xiaofang Xiong, Rong Lv
Liraglutide is glucagon‑like peptide‑1 receptor agonist used for treating patients with type 2 diabetes mellitus. The present study aimed to investigate the role and mechanism of liraglutide in repairing the infarcted heart following myocardial infarction. The results of the present study demonstrated that amplification of the dose of liraglutide for ~28 days was able to reduce cardiac fibrosis, inflammatory responses and myocardial death in the post‑infarcted heart. In vitro, liraglutide protected cardiomyocyte mitochondria against the chronic hypoxic damage, inhibiting the mitochondrial apoptosis pathways...
January 2, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29326146/prior-authorization-requirements-for-proprotein-convertase-subtilisin-kexin-type-9-inhibitors-across-us-private-and-public-payers
#12
Jalpa A Doshi, Justin T Puckett, Michael S Parmacek, Daniel J Rader
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an innovative treatment option for patients with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require further lowering of low-density lipoprotein cholesterol. However, the high costs of these agents have spurred payers to implement utilization management policies to ensure appropriate use. We examined prior authorization (PA) requirements for PCSK9is across private and public US payers...
January 2018: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/29310645/effects-of-6-month-treatment-with-the-glucagon-like-peptide-1-analogue-liraglutide-on-arterial-stiffness-left-ventricular-myocardial-deformation-and-oxidative-stress-in-subjects-with-newly-diagnosed-type-2-diabetes
#13
Vaia Lambadiari, George Pavlidis, Foteini Kousathana, Maria Varoudi, Dimitrios Vlastos, Eirini Maratou, Dimitrios Georgiou, Ioanna Andreadou, John Parissis, Helen Triantafyllidi, John Lekakis, Efstathios Iliodromitis, George Dimitriadis, Ignatios Ikonomidis
BACKGROUND: Incretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-month treatment with the GLP-1 analogue liraglutide in subjects with newly diagnosed T2DM. METHODS: We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months...
January 8, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29305933/effects-of-weight-loss-medications-on-cardiometabolic-risk-profiles-a-systematic-review-and-network-meta-analysis
#14
Rohan Khera, Ambarish Pandey, Apoorva K Chandar, Mohammad H Murad, Larry J Prokop, Ian J Neeland, Jarett Berry, Michael Camilleri, Siddharth Singh
BACKGROUND & AIMS: We performed a systematic review and network meta-analysis to evaluate the overall and comparative effects of weight-loss medications, approved by the Food and Drug Administration (FDA) for long-term use, on cardiometabolic risk profiles of obese adults. METHODS: We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of FDA-approved weight loss medications (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide), administered to obese adults for 1 year or more, compared with placebo or another active agent...
January 3, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29305122/liraglutide-ameliorates-cognitive-decline-by-promoting-autophagy-via-the-amp-activated-protein-kinase-mammalian-target-of-rapamycin-pathway-in-a-streptozotocin-induced-mouse-model-of-diabetes
#15
Fei-Juan Kong, Jia-Hua Wu, Shui-Ya Sun, Lei-Lei Ma, Jia-Qiang Zhou
Diabetic cognitive dysfunction has gained widespread attention for its deleterious impact on individuals with diabetes. However, few clinical interventions are available to prevent the disorder. The glucagon-like peptide-1 analog liraglutide exerts neuroprotective effects in several models of neurodegenerative diseases. We investigated the effect of liraglutide pretreatment on diabetes-induced cognitive decline and explored the underlying mechanisms in vivo and in vitro. Liraglutide pretreatment prevented diabetes-induced cognitive impairment as assessed by the Morris Water Maze test, and alleviated neuronal injuries and ultrastructural damage to synapses in the hippocampal CA1 region...
January 2, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29301630/obesity-pathophysiology-and%C3%A2-management
#16
REVIEW
Kishore M Gadde, Corby K Martin, Hans-Rudolf Berthoud, Steven B Heymsfield
Obesity continues to be among the top health concerns across the globe. Despite our failure to contain the high prevalence of obesity, we now have a better understanding of its pathophysiology, and how excess adiposity leads to type 2 diabetes, hypertension, and cardiovascular disease. Lifestyle modification is recommended as the cornerstone of obesity management, but many patients do not achieve long-lasting benefits due to difficulty with adherence as well as physiological and neurohormonal adaptation of the body in response to weight loss...
January 2, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29295870/effect-of-liraglutide-on-atrial-natriuretic-peptide-adrenomedullin-and-copeptin-in-pcos
#17
Signe Frøssing, Malin Nylander, Caroline Kistorp, Sven O Skouby, Jens Faber
CONTEXT: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease (CVD), and biomarkers can be used to detect early subclinical CVD. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial natriuretic peptide (MR-proANP) and copeptin are all associated with CVD and part of the delicate system controlling fluid and hemodynamic homeostasis through vascular tonus and diuresis. The GLP-1 receptor agonist liraglutide, developed for treatment of type 2 diabetes (T2D), improves cardiovascular outcomes in patients with T2D including a decrease in particular MR-proANP...
January 2018: Endocrine Connections
https://www.readbyqxmd.com/read/29290651/mir-192-5p-regulates-lipid-synthesis-in-non-alcoholic-fatty-liver-disease-through-scd-1
#18
Xiao-Lin Liu, Hai-Xia Cao, Bao-Can Wang, Feng-Zhi Xin, Rui-Nan Zhang, Da Zhou, Rui-Xu Yang, Ze-Hua Zhao, Qin Pan, Jian-Gao Fan
AIM: To evaluate the levels of miR-192-5p in non-alcoholic fatty liver disease (NAFLD) models and demonstrate the role of miR-192-5p in lipid accumulation. METHODS: Thirty Sprague Dawley rats were randomly divided into three groups, which were given a standard diet, a high-fat diet (HFD), and an HFD with injection of liraglutide. At the end of 16 weeks, hepatic miR-192-5p and stearoyl-CoA desaturase 1 (SCD-1) levels were measured. MiR-192-5p mimic and inhibitor and SCD-1 siRNA were transfected into Huh7 cells exposed to palmitic acid (PA)...
December 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29279300/no-evidence-of-increase-in-calcitonin-concentrations-or-development-of-c-cell-malignancy-in-response-to-liraglutide-for-up-to-5-years-in-the-leader-trial
#19
Laszlo Hegedüs, Steven I Sherman, R Michael Tuttle, Bernt J von Scholten, Søren Rasmussen, Julie D Karsbøl, Gilbert H Daniels
OBJECTIVE: To describe the changes in serum levels of calcitonin in liraglutide- and placebo-treated patients in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial over a 3.5-5-year period. RESEARCH DESIGN AND METHODS: Patients (n = 9,340) with type 2 diabetes and high risk for cardiovascular events were randomized 1:1 to liraglutide or placebo. We analyzed calcitonin levels throughout the trial, and thyroid and C-cell adverse events and neoplasms...
December 26, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29277968/efficacy-and-safety-of-adding-liraglutide-to-existing-insulin-regimens-in-japanese-subjects-with-type-2-diabetes-mellitus-a-post-hoc-analysis-of-a-phase-3-randomized-clinical-trial
#20
Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch-Traberg, Kohei Kaku, Yutaka Seino
AIMS: To determine the efficacy and safety of adding liraglutide to three different insulin regimens in Japanese subjects with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: In this post hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported. Subjects with T2DM were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix). The primary objective was to determine whether adding liraglutide (0...
December 26, 2017: Journal of Diabetes Investigation
keyword
keyword
20037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"